Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM SD
Specialized Disclosure Report
SeaSpine Holdings Corporation
(Exact Name of Registrant as Specified in its Charter)
|
| | |
Delaware | 001-36905 | 47-3251758 |
(State or Other Jurisdiction of Incorporation) | (Commission File No.) | (I.R.S. Employer Identification No.) |
5770 Armada Drive
Carlsbad, California 92008
(Address of Principal Executive Offices, Including Zip Code)
Patrick Keran
(760) 727-8399
(Name and Telephone Number, Including Area Code, of the Person to Contact in connection with this Report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
|
| |
ý | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2015
|
Section 1 - Conflict Minerals Disclosure
| |
Item 1.01 | Conflict Minerals Disclosure and Report |
Conflict Minerals Disclosure
Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) defines “Conflict Minerals” as columbite-tantalite (coltan), cassiterite, wolframite (and their derivatives tantalum, tin and tungsten) and gold, and defines the “Covered Countries” as the Democratic Republic of the Congo or an adjoining country. From July 1, 2015 through December 31, 2015, SeaSpine Holdings Corporation, through its subsidiaries, sold certain medical devices that contained Conflict Minerals. In accordance with the rules promulgated pursuant to the Dodd-Frank Act, we conducted a reasonable country of origin inquiry with respect to Conflict Minerals that were contained in the medical devices that we sold in 2015 and were not outside of the supply chain prior to January 31, 2013. All of these medical devices were manufactured for us by third party suppliers.
To conduct our reasonable country of origin inquiry, we engaged with third party suppliers of our medical devices that we determined contained Conflict Minerals and made inquiries to those suppliers regarding the source of those Conflict Minerals. In making such inquiry, we used the Conflict Minerals Reporting Template developed by the Conflict-Free Sourcing Initiative to request information from such suppliers about their supply chain and to gather information about the country of origin of the Conflict Minerals contained in our products. All such suppliers provided the name of the smelter that processed such Conflict Minerals and declared that the Conflict Minerals contained in materials supplied to us were not sourced from Covered Countries.
Conclusion
Based on our reasonable country of origin inquiry, we have no reason to believe that any Conflict Minerals contained in medical devices manufactured for us in 2015 originated in any Covered Country.
This Conflict Minerals Disclosure is also available on our website at: http://sec.seaspine.com.
Not required.
Section 2 - Exhibits
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| | | |
| | SEASPINE HOLDINGS CORPORATION |
| | | |
Date: May 26, 2016 | | By | /s/ Patrick Keran |
| | | Patrick Keran |
| | | Vice President, General Counsel |